Newtown, PA, December 12, 2020.
STI Pharma, LLC (“STI”) announced the US launch of Succinylcholine® for injection, 200mg/10mL mg strength.
Succinylcholine® for Injection is the AP rated generic equivalent of the skeletal muscle relaxant Anectine. According to IQVIA™, a leading healthcare data and analytics provider, U.S. annual sales for Succinylcholine® for Injection, USP, for the 12 months ending November 2020 were approximately $67 million
Succinylcholine® chloride is indicated as an adjunct to general anesthesia, to facilitate tracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation.
Important Safety information, there have been rare reports of acute rhabdomyolysis with hyperkalemia followed by ventricular dysrhythmias, cardiac arrest and death after administration of Succinylcholine® to apparently health pediatric patients who were subsequently found to have undiagnosed skeletal muscle myopathy, most frequently Duchenne’s muscular dystrophy.
Reported adverse reactions Adverse reactions to Succinylcholine® consist primarily of an extension of its pharmacological actions. Succinylcholine® causes profound muscle relaxation resulting in respiratory depression to the point of apnea; this effect may be prolonged. Hypersensitivity reactions, including anaphylaxis, may occur in rare instances. The following additional adverse reactions have been reported: cardiac arrest, malignant hyperthermia, arrhythmias, bradycardia, tachycardia, hypertension, hypotension, hyperkalemia, prolonged respiratory depression or apnea, increased intraocular pressure, muscle fasciculation, jaw rigidity, postoperative muscle pain, and rhabdomyolysis with possible myoglobinuric acute renal failure, excessive salivation, and rash.
See Package Insert (PI) for full prescribing information and complete safety information: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b336b8e5-f795-ee89-e053-2a95a90a6bbe